41. Previously, no other anticancer treatment had worked. 42. Boston Scientific chose paclitaxel, an anticancer compound. 43. This allows for faster and more objective assessment of the effects of anticancer drugs. 44. The factors promote neutrophil recovery following anticancer therapy. 45. Synthetic derivatives of artemisinin are being investigated for their potential use as anticancer drugs. 46. UBE2L3 depletion may become a novel strategy in enhancing the effect of anticancer therapies. 47. SIRT2-specific inhibitors exhibits broad anticancer activity. 48. It has even stronger anticancer activity than nogalamycin and has less toxicity than nogalamycin. 49. This ability further contributes to its anticancer potential. 50. They were developed for their anticancer chemotherapeutic properties.
